



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

**#53196**

**Date:** September 14, 2023

**Subject:** BCTX1 Options - Expiration Pricing Consideration

BCTX1 (adjusted BriaCell Therapeutics Corporation options) will be subject to special pricing consideration in expiration processing on September 15, 2023. The pricing consideration is due to the undetermined trading status of the SpinCo shares included in the BCTX1 options deliverable. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

### **BCTX1**

BCTX1 options are adjusted BriaCell Therapeutics Corporation options, adjusted September 5, 2023 (see OCC Information Memo #53128). The deliverable of BCTX1 options is:

#### **DELIVERABLE**

**PER CONTRACT:**

- 1) 100 BriaCell Therapeutics Corporation (BCTX) Common Shares
- 2) 100 BriaPro Therapeutics Corporation Common Shares (subject to delayed settlement until the trading status can be determined).

As of September 14, 2023, the trading status for the SpinCo shares has yet to be determined.

For purposes of calculating BCTX1 price for use in expiration processing, OCC will use the following formula:

$$\text{BCTX1} = \text{BCTX}$$

For example, if BCTX closes at 6.12, the BCTX1 price would be:

$$\text{BCTX1} = 6.12$$

This formula does not include an estimate of the value of the BriaPro Therapeutics Corporation Common Shares.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).